Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.27
MCK's Cash-to-Debt is ranked lower than
75% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.74 vs. MCK: 0.27 )
Ranked among companies with meaningful Cash-to-Debt only.
MCK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.54 Max: N/A
Current: 0.27
Equity-to-Asset 0.13
MCK's Equity-to-Asset is ranked lower than
96% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.42 vs. MCK: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
MCK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.27 Max: 0.35
Current: 0.13
0.13
0.35
Interest Coverage 9.85
MCK's Interest Coverage is ranked lower than
53% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.37 vs. MCK: 9.85 )
Ranked among companies with meaningful Interest Coverage only.
MCK' s Interest Coverage Range Over the Past 10 Years
Min: 7.94  Med: 9.12 Max: 12.77
Current: 9.85
7.94
12.77
Piotroski F-Score: 6
Altman Z-Score: 4.18
Beneish M-Score: -2.81
WACC vs ROIC
7.83%
17.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 1.59
MCK's Operating Margin % is ranked lower than
66% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.78 vs. MCK: 1.59 )
Ranked among companies with meaningful Operating Margin % only.
MCK' s Operating Margin % Range Over the Past 10 Years
Min: 1.12  Med: 1.7 Max: 1.92
Current: 1.59
1.12
1.92
Net Margin % 0.97
MCK's Net Margin % is ranked lower than
70% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.65 vs. MCK: 0.97 )
Ranked among companies with meaningful Net Margin % only.
MCK' s Net Margin % Range Over the Past 10 Years
Min: 0.77  Med: 1.03 Max: 1.18
Current: 0.97
0.77
1.18
ROE % 21.65
MCK's ROE % is ranked higher than
90% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.33 vs. MCK: 21.65 )
Ranked among companies with meaningful ROE % only.
MCK' s ROE % Range Over the Past 10 Years
Min: 13.37  Med: 17.09 Max: 26.68
Current: 21.65
13.37
26.68
ROA % 3.35
MCK's ROA % is ranked lower than
55% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.93 vs. MCK: 3.35 )
Ranked among companies with meaningful ROA % only.
MCK' s ROA % Range Over the Past 10 Years
Min: 2.79  Med: 4.07 Max: 4.73
Current: 3.35
2.79
4.73
ROC (Joel Greenblatt) % 96.19
MCK's ROC (Joel Greenblatt) % is ranked higher than
88% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.27 vs. MCK: 96.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MCK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 63.18  Med: 119.74 Max: 185.28
Current: 96.19
63.18
185.28
3-Year Revenue Growth Rate 17.00
MCK's 3-Year Revenue Growth Rate is ranked higher than
82% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.40 vs. MCK: 17.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MCK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.6  Med: 11.4 Max: 23.7
Current: 17
-13.6
23.7
3-Year EBITDA Growth Rate 18.40
MCK's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.40 vs. MCK: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MCK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.7  Med: 10.6 Max: 171.6
Current: 18.4
-52.7
171.6
3-Year EPS without NRI Growth Rate 20.00
MCK's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.30 vs. MCK: 20.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MCK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.5  Med: 12.8 Max: 87.1
Current: 20
-44.5
87.1
GuruFocus has detected 1 Warning Sign with McKesson Corp $MCK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MCK's 10-Y Financials

Financials (Next Earnings Date: 2017-05-18)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MCK Guru Trades in Q2 2016

Tom Gayner 9,100 sh (New)
Ronald Muhlenkamp 46,183 sh (New)
Jim Simons 97,400 sh (New)
David Dreman 5,004 sh (New)
Steven Cohen 175,700 sh (+1809.78%)
Ray Dalio 33,359 sh (+156.61%)
Diamond Hill Capital 1,382 sh (+0.51%)
Vanguard Health Care Fund 7,165,280 sh (unchged)
Wallace Weitz 57,675 sh (unchged)
Pioneer Investments Sold Out
Dodge & Cox Sold Out
Larry Robbins Sold Out
Paul Tudor Jones Sold Out
John Buckingham 22,267 sh (-0.12%)
Arnold Van Den Berg 68,913 sh (-1.79%)
Scott Black 9,047 sh (-2.86%)
John Paulson 60,500 sh (-3.20%)
First Pacific Advisors 85,300 sh (-5.48%)
Charles Brandes 39,287 sh (-8.49%)
Manning & Napier Advisors, Inc 36,300 sh (-15.35%)
Jerome Dodson 40,000 sh (-50.00%)
Joel Greenblatt 181,378 sh (-50.61%)
Mario Gabelli 5,000 sh (-58.57%)
» More
Q3 2016

MCK Guru Trades in Q3 2016

Paul Tudor Jones 9,323 sh (New)
Eaton Vance Worldwide Health Sciences Fund 193,108 sh (New)
Jim Simons 758,300 sh (+678.54%)
Charles Brandes 55,134 sh (+40.34%)
Joel Greenblatt 235,225 sh (+29.69%)
Manning & Napier Advisors, Inc 45,250 sh (+24.66%)
Ray Dalio 41,359 sh (+23.98%)
John Paulson 67,000 sh (+10.74%)
Wallace Weitz 58,080 sh (+0.70%)
Jerome Dodson 40,000 sh (unchged)
Vanguard Health Care Fund 7,165,280 sh (unchged)
Tom Gayner 9,100 sh (unchged)
David Dreman 5,004 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 9,035 sh (-0.13%)
John Buckingham 22,140 sh (-0.57%)
Ronald Muhlenkamp 45,753 sh (-0.93%)
Arnold Van Den Berg 67,944 sh (-1.41%)
Diamond Hill Capital 1,360 sh (-1.59%)
First Pacific Advisors 83,080 sh (-2.60%)
» More
Q4 2016

MCK Guru Trades in Q4 2016

Richard Pzena 186,289 sh (New)
Jana Partners 386,868 sh (New)
Steven Cohen 43,100 sh (New)
Seth Klarman 1,000,000 sh (New)
David Tepper 275,000 sh (New)
Larry Robbins 683,516 sh (New)
Charles Brandes 1,045,486 sh (+1796.26%)
Diamond Hill Capital 21,280 sh (+1464.71%)
Jerome Dodson 119,000 sh (+197.50%)
Paul Tudor Jones 26,546 sh (+184.74%)
Ray Dalio 67,759 sh (+63.83%)
Ronald Muhlenkamp 71,767 sh (+56.86%)
Joel Greenblatt 277,057 sh (+17.78%)
Vanguard Health Care Fund 8,218,500 sh (+14.70%)
Mario Gabelli 5,000 sh (unchged)
Tom Gayner 9,100 sh (unchged)
Jim Simons Sold Out
Wallace Weitz Sold Out
John Paulson Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Scott Black 8,813 sh (-2.46%)
Arnold Van Den Berg 66,107 sh (-2.70%)
John Buckingham 21,226 sh (-4.13%)
Manning & Napier Advisors, Inc 38,800 sh (-14.25%)
David Dreman 3,925 sh (-21.56%)
First Pacific Advisors 57,200 sh (-31.15%)
» More
Q1 2017

MCK Guru Trades in Q1 2017

Jerome Dodson 168,000 sh (+41.18%)
Arnold Van Den Berg 80,140 sh (+21.23%)
Tom Gayner 9,100 sh (unchged)
Manning & Napier Advisors, Inc 26,355 sh (-32.07%)
» More
» Details

Insider Trades

Latest Guru Trades with MCK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 424210    SIC: 5122
Compare:NYSE:CAH, NYSE:ABC, NAS:HSIC, OTCPK:SHTDF, NAS:PDCO, NYSE:PBH, NYSE:OMI, OTCPK:EBOSF, NYSE:PMC, OTCPK:SGMFF, OTCPK:SNYR, OTCPK:FZMD » details
Traded in other countries:MCK.Germany, MCK.Mexico,
Headquarter Location:USA
McKesson Corporation distributes pharmaceuticals, medical supplies and healthcare information technology that make healthcare safer while reducing costs. Its segments include McKesson Distribution Solutions and McKesson Technology Solutions.

McKesson is a major distributor of pharmaceuticals, specialty drugs, and medical products in North America. The firm plays a critical role along the pharmaceutical supply chain as it is able to procure and distribute drugs more efficiently than its pharmacy client and pharma manufacturing suppliers.

Guru Investment Theses on McKesson Corp

Weitz Funds Comments on McKesson - Jan 26, 2017

McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 26, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.

From Mario Gabelli (Trades, Portfolio)'s Gabelli Asset Fund second quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 25, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.



From the Gabelli ABC Merger Arbitrage Fund second quarter 2016 shareholder letter.



Check out Mario Gabelli latest stock trades

Parnassus Fund Comments on McKesson - May 09, 2016

McKesson (NYSE:MCK), the largest drug distributor in the nation, sliced 50 basis points from the Fund’s return, as the stock declined 20.3% from $197.23 to $157.25. The stock moved lower after management provided weaker-than-expected guidance due to weaker generic drug prices. McKesson also lost some drugstore customers, as several chains were acquired by firms using other distributors. Despite these headwinds, we expect revenue to recover through organic growth and attracting new customers. McKesson provides significant value to consumers by improving the efficiency of drug procurement and delivery, which we believe will generate shareholder value over the long term.



From the Parnassus Fund first quarter 2016 shareholder letter.



Check out Jerome Dodson latest stock trades

Wallace Weitz Comments on McKesson - Apr 22, 2016

McKesson (NYSE:MCK) distributes drugs, equipment, and health and beauty products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Merger-related customer losses (McKesson accounts Omnicare, Target Pharmacy and Rite Aid are moving to competing wholesalers after being acquired), the return of generic drug deflation and concerns of lower future branded drug inflation combined to drive McKesson’s stock down nearly 40% from its high last summer. Having done detailed work on the company roughly nine years prior, we sharpened our pencils again late last year and initiated a position at $150 in January. The drug wholesaling business is an attractive oligopoly characterized by intense but rational competition, stable growth, healthy returns on capital and consistent excess cash generation. While McKesson’s business faces some near-term headwinds, we believe it is an attractive investment over the long term.

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about McKesson Corp

Jerome Dodson Adds to 9 Positions in 4th Quarter Guru's purchases involve 4 health care-related companies
Parnassus Investments founder and President Jerome Dodson (Trades, Portfolio) made no new buys in the fourth quarter, but he added to nine existing positions in his portfolio. Read more...
Weitz Funds Comments on McKesson Guru stock highlight
McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss. Read more...
Sometimes It Is Good to Buy the Biggest. But Should You Buy the Biggest Health Care Distribution Business? McKesson is a giant that has recently experienced a pullback. Does that make it a good prospect, or would its competitors be better opportunities?
Mario Gabelli Comments on McKesson Corp Guru stock highlight
McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns. Read more...
Mario Gabelli Comments on McKesson Corp Gabelli shareholder letter
McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns. Read more...
Parnassus Fund Comments on McKesson Guru stock highlight
McKesson (NYSE:MCK), the largest drug distributor in the nation, sliced 50 basis points from the Fund’s return, as the stock declined 20.3% from $197.23 to $157.25. The stock moved lower after management provided weaker-than-expected guidance due to weaker generic drug prices. McKesson also lost some drugstore customers, as several chains were acquired by firms using other distributors. Despite these headwinds, we expect revenue to recover through organic growth and attracting new customers. McKesson provides significant value to consumers by improving the efficiency of drug procurement and delivery, which we believe will generate shareholder value over the long term. Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.35
MCK's PE Ratio is ranked higher than
67% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.66 vs. MCK: 16.35 )
Ranked among companies with meaningful PE Ratio only.
MCK' s PE Ratio Range Over the Past 10 Years
Min: 8.17  Med: 18.12 Max: 38.44
Current: 16.35
8.17
38.44
Forward PE Ratio 11.71
MCK's Forward PE Ratio is ranked higher than
90% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.08 vs. MCK: 11.71 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.25
MCK's PE Ratio without NRI is ranked higher than
69% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.98 vs. MCK: 15.25 )
Ranked among companies with meaningful PE Ratio without NRI only.
MCK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.17  Med: 17.8 Max: 33.83
Current: 15.25
8.17
33.83
Price-to-Owner-Earnings 5.50
MCK's Price-to-Owner-Earnings is ranked higher than
93% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.77 vs. MCK: 5.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MCK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.4  Med: 12.51 Max: 38.54
Current: 5.5
5.4
38.54
PB Ratio 4.06
MCK's PB Ratio is ranked lower than
85% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.47 vs. MCK: 4.06 )
Ranked among companies with meaningful PB Ratio only.
MCK' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.9 Max: 6.98
Current: 4.06
1.31
6.98
PS Ratio 0.16
MCK's PS Ratio is ranked higher than
88% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.13 vs. MCK: 0.16 )
Ranked among companies with meaningful PS Ratio only.
MCK' s PS Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.18 Max: 0.32
Current: 0.16
0.08
0.32
Price-to-Free-Cash-Flow 5.50
MCK's Price-to-Free-Cash-Flow is ranked higher than
95% of the 22 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.56 vs. MCK: 5.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MCK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.41  Med: 12.44 Max: 43.64
Current: 5.5
5.41
43.64
Price-to-Operating-Cash-Flow 4.96
MCK's Price-to-Operating-Cash-Flow is ranked higher than
96% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.03 vs. MCK: 4.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MCK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 10.41 Max: 98.78
Current: 4.96
4.87
98.78
EV-to-EBIT 11.29
MCK's EV-to-EBIT is ranked higher than
67% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.81 vs. MCK: 11.29 )
Ranked among companies with meaningful EV-to-EBIT only.
MCK' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.7  Med: 11.5 Max: 22.1
Current: 11.29
5.7
22.1
EV-to-EBITDA 8.87
MCK's EV-to-EBITDA is ranked higher than
79% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.78 vs. MCK: 8.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
MCK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 9.2 Max: 16.3
Current: 8.87
4.5
16.3
PEG Ratio 0.89
MCK's PEG Ratio is ranked higher than
81% of the 27 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.00 vs. MCK: 0.89 )
Ranked among companies with meaningful PEG Ratio only.
MCK' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.19 Max: 8.81
Current: 0.89
0.16
8.81
Shiller PE Ratio 23.43
MCK's Shiller PE Ratio is ranked higher than
61% of the 18 Companies
in the Global Medical Distribution industry.

( Industry Median: 30.82 vs. MCK: 23.43 )
Ranked among companies with meaningful Shiller PE Ratio only.
MCK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.98  Med: 29.77 Max: 51.63
Current: 23.43
14.98
51.63
Current Ratio 1.03
MCK's Current Ratio is ranked lower than
88% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.62 vs. MCK: 1.03 )
Ranked among companies with meaningful Current Ratio only.
MCK' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.27 Max: 1.71
Current: 1.03
1.03
1.71
Quick Ratio 0.61
MCK's Quick Ratio is ranked lower than
86% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.07 vs. MCK: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
MCK' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 0.66 Max: 0.94
Current: 0.61
0.52
0.94
Days Inventory 31.00
MCK's Days Inventory is ranked higher than
65% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 41.10 vs. MCK: 31.00 )
Ranked among companies with meaningful Days Inventory only.
MCK' s Days Inventory Range Over the Past 10 Years
Min: 29.7  Med: 31.71 Max: 32.98
Current: 31
29.7
32.98
Days Sales Outstanding 33.80
MCK's Days Sales Outstanding is ranked higher than
79% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 53.92 vs. MCK: 33.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
MCK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.03  Med: 26.2 Max: 33.8
Current: 33.8
22.03
33.8
Days Payable 60.73
MCK's Days Payable is ranked lower than
55% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 65.77 vs. MCK: 60.73 )
Ranked among companies with meaningful Days Payable only.
MCK' s Days Payable Range Over the Past 10 Years
Min: 44.77  Med: 50.99 Max: 60.73
Current: 60.73
44.77
60.73

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.81
MCK's Dividend Yield % is ranked lower than
87% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.91 vs. MCK: 0.81 )
Ranked among companies with meaningful Dividend Yield % only.
MCK' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.67 Max: 1.42
Current: 0.81
0.35
1.42
Dividend Payout Ratio 0.12
MCK's Dividend Payout Ratio is ranked higher than
88% of the 34 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.32 vs. MCK: 0.12 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MCK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.13 Max: 0.17
Current: 0.12
0.07
0.17
3-Year Dividend Growth Rate 10.50
MCK's 3-Year Dividend Growth Rate is ranked lower than
60% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.50 vs. MCK: 10.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MCK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -21.7  Med: 0 Max: 44.2
Current: 10.5
-21.7
44.2
Forward Dividend Yield % 0.81
MCK's Forward Dividend Yield % is ranked lower than
78% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.91 vs. MCK: 0.81 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.20
MCK's 5-Year Yield-on-Cost % is ranked lower than
90% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.58 vs. MCK: 1.20 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MCK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 2.1
Current: 1.2
0.52
2.1
3-Year Average Share Buyback Ratio 0.30
MCK's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 35 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.40 vs. MCK: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MCK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47  Med: -0.5 Max: 5.7
Current: 0.3
-47
5.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.64
MCK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 27 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.59 vs. MCK: 0.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MCK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.02 Max: 30.68
Current: 0.64
0.55
30.68
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.82
MCK's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 9 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.39 vs. MCK: 0.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.89
MCK's Price-to-Median-PS-Value is ranked higher than
64% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.01 vs. MCK: 0.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MCK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.03 Max: 2.32
Current: 0.89
0.51
2.32
Price-to-Peter-Lynch-Fair-Value 1.01
MCK's Price-to-Peter-Lynch-Fair-Value is ranked higher than
85% of the 13 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.01 vs. MCK: 1.01 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MCK' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.2 Max: 72.67
Current: 1.01
0.34
72.67
Earnings Yield (Greenblatt) % 8.86
MCK's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.75 vs. MCK: 8.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MCK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.5  Med: 8.7 Max: 17.6
Current: 8.86
4.5
17.6
Forward Rate of Return (Yacktman) % 23.59
MCK's Forward Rate of Return (Yacktman) % is ranked higher than
81% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.60 vs. MCK: 23.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MCK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.1  Med: 20.8 Max: 94.3
Current: 23.59
-3.1
94.3

More Statistics

Revenue (TTM) (Mil) $196,498
EPS (TTM) $ 8.46
Beta1.18
Short Percentage of Float1.88%
52-Week Range $114.53 - 199.43
Shares Outstanding (Mil)212.05

Analyst Estimate

Mar17 Mar18 Mar19
Revenue (Mil $) 199,644 203,205 214,112
EPS ($) 12.56 12.05 12.68
EPS without NRI ($) 12.56 12.05 12.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.67%
Dividends per Share ($) 1.08 1.08 1.26
» More Articles for MCK

Headlines

Articles On GuruFocus.com
Is Cardinal Health a Better Bargain Than Ever? Apr 18 2017 
The Threat and Risk of Rising Interest Rates: Separating Fact From Fiction Mar 24 2017 
Seth Klarman's Largest 4th-Quarter Buys Mar 16 2017 
Jerome Dodson Adds to 9 Positions in 4th Quarter Mar 01 2017 
Jana Partners' Largest 4th-Quarter Buys Mar 01 2017 
Searching For Value Feb 27 2017 
Weitz Funds Comments on McKesson Jan 26 2017 
Integer Investments: Drug Distributors Are Good Investments Jan 04 2017 
The AmerisourceBergen-Walgreens Boots Alliance Connection Dec 16 2016 
Analysis of AmerisourceBergen's Dividend Increase Nov 17 2016 

More From Other Websites
Arkansas will face challenges replenishing execution supply Apr 29 2017
There are only nine five-star U.S. stocks, but don’t panic: Morningstar CEO Apr 26 2017
Jerome Dodson Keeps Buying McKesson, Axalta, Pentair Apr 25 2017
Drugmaker asked Arkansas not to use drug in executions Apr 21 2017
Arkansas conducts first execution since 2005, plans 3 more Apr 21 2017
Arkansas overcomes legal hurdles, carries out execution Apr 21 2017
Arkansas executes first inmate in 12 years Apr 21 2017
Arkansas court allows execution drug hours ahead of lethal injection Apr 20 2017
McKesson Corporation Fiscal 2017 Fourth Quarter Conference Call Scheduled for May 18, 2017 Apr 20 2017
The Latest: Arkansas governor disappointed by court ruling Apr 19 2017
Arkansas suffers 2 setbacks to multiple execution plan Apr 19 2017
[$$] Cardinal Health’s $6.1 Billion Deal for Some Medtronic Operations Raises Debt Concerns Apr 19 2017
Company sues Arkansas, charging fraud over lethal injection drugs Apr 18 2017
US Supreme Court spares Arkansas inmate from execution Apr 18 2017
The makers of a lethal-injection drug have become leaders in Arkansas' death-penalty battle Apr 17 2017
Judge halts Arkansas plan to execute 8 inmates in 11 days Apr 15 2017
Arkansas' multiple execution plan appearing to unravel Apr 14 2017
Latest: Arkansas judge blocks state from using lethal drug Apr 14 2017
Pfizer Says Execution Drugs Sold to Arkansas Without Knowing Apr 13 2017
McKesson's $157M Irving campus prescribes health for up to 2,500 workers Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)